Insulin resistance and atherosclerosis

Journal of Clinical Investigation

Volumn 116, Issue 7, 2006, Pages 1813-1822

  Semenkovich, Clay F ^a  

^a WASHINGTON UNIVERSITY SCHOOL OF MEDICINE   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

2,4 THIAZOLIDINEDIONE DERIVATIVE; ATENOLOL; ATORVASTATIN; BEZAFIBRATE; CANNABINOID 1 RECEPTOR; CLOFIBRATE; DIPEPTIDYL CARBOXYPEPTIDASE INHIBITOR; FENOFIBRATE; FIBRIC ACID DERIVATIVE; GEMFIBROZIL; GLITAZONE DERIVATIVE; GW 7647; HYDROXYMETHYLGLUTARYL COENZYME A REDUCTASE INHIBITOR; IMATINIB; LOSARTAN; LOW DENSITY LIPOPROTEIN CHOLESTEROL; METFORMIN; PEROXISOME PROLIFERATOR ACTIVATED RECEPTOR; PEROXISOME PROLIFERATOR ACTIVATED RECEPTOR ALPHA AGONIST; PEROXISOME PROLIFERATOR ACTIVATED RECEPTOR GAMMA AGONIST; PIOGLITAZONE; PRAVASTATIN; RAMIPRIL; RIMONABANT; SIMVASTATIN; SULFONYLUREA; THYROID HORMONE;

ABNORMALLY HIGH SUBSTRATE CONCENTRATION IN BLOOD; ANXIETY; ATHEROSCLEROSIS; CELL NUCLEUS; CHOLESTEROL BLOOD LEVEL; CLINICAL TRIAL; DEPRESSION; DISEASE ASSOCIATION; DYSLIPIDEMIA; ENDOPLASMIC RETICULUM; GLUCOSE INTOLERANCE; HEART FAILURE; HUMAN; HYPERGLYCEMIA; HYPERLIPIDEMIA; HYPERTENSION; INSULIN RESISTANCE; INSULIN SENSITIVITY; ISCHEMIC HEART DISEASE; METABOLIC SYNDROME X; MITOCHONDRIAL TOXICITY; NAUSEA; NON INSULIN DEPENDENT DIABETES MELLITUS; NONHUMAN; OBESITY; PRIORITY JOURNAL; REVIEW; SIDE EFFECT; VASCULAR DISEASE; WEIGHT GAIN;

ANIMALS; ATHEROSCLEROSIS; CELL NUCLEUS; DYSLIPIDEMIAS; ENDOPLASMIC RETICULUM; HUMANS; HYPERGLYCEMIA; HYPERTENSION; INSULIN RESISTANCE; MITOCHONDRIA; OXIDATIVE STRESS; PEROXISOME PROLIFERATOR-ACTIVATED RECEPTORS;

EID: 33745828640     PISSN: 00219738     EISSN: 15588238     Source Type: Journal    
DOI: 10.1172/JCI29024     Document Type: Review

References (125)

1. Enzi, G., Busetto, L., Inelmen, E.M., Coin, A., and Sergi, G. 2003. Historical perspective: visceral obesity and related comorbidity in Joannes Baptista Morgagni's 'De sedibus et causis morborum per anatomen indagata.' Int. J. Obes. Relat. Metab. Disord. 27:534-535.
2. Himsworth, H. 1939. The mechanism of diabetes mellitus. III. Human diabetes mellitus. Lancet. 2:171-175.
3. Albrink, M.J., and Mann, E.B. 1958. Serum triglycerides in coronary artery disease. Trans. Assoc. Am. Physicians. 71:162-173.
4. Yalow, R.S., and Berson, S.A. 1960. Immunoassay of endogenous plasma insulin in man. J. Clin. Invest. 39:1157-1175.
5. Reaven, G., Calciano, A., Cody, R., Lucas, C., and Miller, R. 1963. Carbohydrate intolerance and hyperlipemia in patients with myocardial infarction without known diabetes mellitus. J. Clin. Endocrinol. Metab. 23:1013-1023.
6. Reaven, G.M. 1988. Banting lecture 1988. Role of insulin resistance in human disease. Diabetes. 37:1595-1607.
7. Alexander, C.M., Landsman, P.B., Teutsch, S.M., and Haffner, S.M. 2003. NCEP-defined metabolic syndrome, diabetes, and prevalence of coronary heart disease among NHANES III participants age 50 years and older. Diabetes. 52:1210-1214.
8. Malik, S., et al. 2004. Impact of the metabolic syndrome on mortality from coronary heart disease, cardiovascular disease, and all causes in United States adults. Circulation. 110:1245-1250.
9. Villena, J.A., Roy, S., Sarkadi-Nagy, E., Kim, K.H., and Sul, H.S. 2004. Desnutrin, an adipocyte gene encoding a novel patratin domain-containing protein, is induced by fasting and glucocorticoids: ectopic expression of desnutrin increases triglyceride hydrolysis. J. Biol. Chem. 279:47066-47075.
10. Foley, J.E. 1992. Rationale and application of fatty acid oxidation inhibitors in treatment of diabetes mellitus. Diabetes Care. 15:773-784.
11. Ginsberg, H.N. 2006. Review: efficacy and mechanisms of action of statins in the treatment of diabetic dyslipidemia. J. Clin. Endocrinol. Metab. 91:383-392.
12. Szapary, P.O., and Rader, D.J. 2004. The triglyceride-high-density lipoprotein axis: an important target of therapy? Am. Heart J. 148:211-221.
13. Cavaghan, M.K., Ehrmann, D.A., and Polonsky, K.S. 2000. Interactions between insulin resistance and insulin secretion in the development of glucose intolerance. J. Clin. Invest. 106:329-333.
14. Coutinho, M., Gerstein, H.C., Wang, Y., and Yusuf, S. 1999. The relationship between glucose and incident cardiovascular events. A metaregression analysis of published data from 20 studies of 95,783 individuals followed for 12.4 years. Diabetes Care. 22:233-240.
15. Khaw, K.T., et al. 2004. Association of hemoglobin A1c with cardiovascular disease and mortality in adults: the European prospective investigation into cancer in Norfolk. Ann. Intern. Med. 141:413-420.
16. Grekin, R.J., Vollmer, A.P., and Sider, R.S. 1995. Pressor effects of portal venous oleate infusion. A proposed mechanism for obesity hypertension. Hypertension. 26:193-198.
17. Morse, S.A., Zhang, R., Thakur, V., and Reisin, E. 2005. Hypertension and the metabolic syndrome. Am. J. Med. Sci. 330:303-310.
18. Bernal-Mizrachi, C., et al. 2002. Respiratory uncoupling lowers blood pressure through a leptindependent mechanism in genetically obese mice. Arterioscler. Thromb. Vasc. Biol. 22:961-968.
19. Bonora, E., et al. 1998. Prevalence of insulin resistance in metabolic disorders: the Bruneck Study. Diabetes. 47:1643-1649.
20. Heart Protection Study Collaborative Group. 2002. MRC/BHF Heart Protection Study of cholesterol lowering with simvastatin in 20,536 high-risk individuals: a randomized placebo-controlled trial. Lancet. 360:7-22.
21. Collins, R., Armitage, J., Parish, S., Sleigh, P., and Peto, R. 2003. MRC/BHF Heart Protection Study of cholesterol-lowering with simvastatin in 5,963 people with diabetes: a randomised placebo-controlled trial. Lancet. 361:2005-2016.
22. Colhoun, H.M., et al. 2004. Primary prevention of cardiovascular disease with atorvastatin in type 2 diabetes in the Collaborative Atorvastatin Diabetes Study (CARDS): multicentre randomized placebo-controlled trial. Lancet. 364:685-696.
23. Keech, A., et al. 2003. Secondary prevention of cardiovascular events with long-term pravastatin in patients with diabetes or impaired fasting glucose. Diabetes Care. 26:2713-2721.
24. Yusuf, S., et al. 2000. Effects of an angiotensin-converting-enzyme inhibitor, ramipril, on cardiovascular events in high-risk patients. N. Engl. J. Med. 342:145-153.
25. Hansson, L., et al. 1999. Effect of angiotensin-converting-enzyme inhibition compared with conventional therapy on cardiovascular morbidity and mortality in hypertension: the Captopril Prevention Project (CAPP) randomized trial. Lancet. 353:611-616.
26. Lindholm, L.H., et al. 2002. Cardiovascular morbidity and mortality in patients with diabetes in the Losartan Intervention for Endpoint reduction in hypertension study (LIFE): a randomized trial against atenolol. Lancet. 359:1004-1010.
27. Ducimetiere, P., et al. 1980. Relationship of plasma insulin levels to the incidence of myocardial infarction and coronary heart disease mortality in a middle-aged population. Diabetologia. 19:205-210.
28. Pyorala, K. 1979. Relationship of glucose tolerance and plasma insulin to the incidence of coronary heart disease: results from two population studies in Finland. Diabetes. 2:131-141.
29. Orchard, T.J., et al. 1994. Insulin as a predictor of coronary heart disease: interaction with apolipoprotein E phenotype. A report from the Multiple Risk Factor Intervention Trial. Ann. Epidemiol. 4:40-45.
30. Wingard, D.L., Barrett-Connor, E.L., and Ferrara, A. 1995. Is insulin really a heart disease risk factor? Diabetes Care. 18:1299-1304.
31. Howard, G., et al. 1996. Insulin sensitivity and atherosclerosis. The Insulin Resistance Atherosclerosis Study (IRAS) Investigators. Circulation. 93:1809-1817.
32. Kahn, R., Buse, J., Ferrannini, E., and Stern, M. 2005. The metabolic syndrome: time for a critical appraisal. Joint statement from the American Diabetes Association and the European Association for the Study of Diabetes. Diabetes Care. 28:2289-2304.
33. McNeill, A.M., et al. 2005. The metabolic syndrome and 11-year risk of incident cardiovascular disease in the Atherosclerosis Risk in Communities study. Diabetes Care. 28:385-390.
34. Wannamethee, S.G., Shaper, A.G., Lennon, L., and Morris, R.W. 2005. Metabolic syndrome vs Framingham Risk Score for prediction of coronary heart disease, stroke, and type 2 diabetes mellitus. Arch. Intern. Med. 165:2644-2650.
35. Berger, J.P., Akiyama, T.E., and Meinke, P.T. 2005. PPARs: therapeutic targets for metabolic disease. Trends Pharmacol. Sci. 26:244-251.
36. Guerre-Millo, M., et al. 2000. Peroxisome proliferative-activated receptor alpha activators improve insulin sensitivity and reduce adiposity. J. Biol. Chem. 275:16638-16642.
37. Chou, C.J., et al. 2002. WY14,643, a peroxisome proliferative-activated receptor alpha (PPARalpha) agonist, improves hepatic and muscle steatosis and reverses insulin resistance in lipoatrophic A-Zip/F-1 mice. J. Biol. Chem. 277:24484-24489.
38. Duez, H., et al. 2002. Reduction of atherosclerosis by the peroxisome proliferative-activated receptor alpha agonist fenofibrate in mice. J. Biol. Chem. 277:48051-48057.
39. Tenenbaum, A., et al. 2004. Peroxisome proliferator-activated receptor ligand bezafibrate for prevention of type 2 diabetes mellitus in patients with coronary artery disease. Circulation. 109:2197-2202.
40. Li, A.C., et al. 2000. Peroxisome proliferator-activated receptor γ ligands inhibit development of atherosclerosis in LDL receptor-deficient mice. J. Clin. Invest. 106:523-531.
41. Li, A.C., et al. 2004. Differential inhibition of macrophage foam-cell formation and atherosclerosis in mice by PPARα, β/δ, and γ. J. Clin. Invest. 114:1564-1576. doi:10.1172/JCI200418730.
42. Hennuyer, N., et al. 2005. PPARα, but not PPARγ, activators decrease macrophage-laden atherosclerotic lesions in a nondiabetic mouse model of mixed dyslipidemia. Arterioscler. Thromb. Vasc. Biol. 25:1897-1902.
43. [Anonymous]. 1978. A co-operative trial in the primary prevention of ischaemic heart disease using clofibrate. Report from the Committee of Principal Investigators. Br. Heart J. 40:1069-1118.
44. Oliver, M.F., Heady, J.A., Morris, J.N., and Cooper, J. 1980. W.H.O. cooperative trial on primary prevention of ischaemic heart disease using clofibrate to lower serum cholesterol: mortality follow-up. Report of the committee of principal investigators. Lancet. 316:379-385.
45. Oliver, M.F., Heady, J.A., Morris, J.N., and Cooper, J. 1984. W.H.O. cooperative trial on primary prevention of ischaemic heart disease with clofibrate to lower serum cholesterol: final mortality follow-up. Report of the committee of principal investigators. Lancet. 324:600-604.
46. Frick, M.H., et al. 1987. Helsinki Heart Study: primary-prevention trial with gemfibrozil in middleaged men with dyslipidemia. Safety of treatment, changes in risk factors, and incidence of coronary heart disease. N. Engl. J. Med. 317:1237-1245.
47. Rubins, H.B., et al. 1999. Gemfibrozil for the secondary prevention of coronary heart disease in men with low levels of high-density lipoprotein cholesterol. Veterans Affairs High-Density Lipoprotein Cholesterol Intervention Trial Study Group. N. Engl. J. Med. 341:410-418.
48. The BIP Study Group. 2000. Secondary Prevention by raising HDL cholesterol and reducing triglycerides in patients with coronary artery disease. The Bezafibrate Infarction Prevention (BIP) study. Circulation. 102:21-27.
49. The FIELD study investigators. 2005. Effects of long-term fenofibrate therapy on cardiovascular events in 9,795 people with type 2 diabetes mellitus (the FIELD study): randomised clinical trial. Lancet. 366:1849-1861.
50. Dormandy, J.A., et al. 2005. Secondary prevention of macrovascular events in patients with type 2 diabetes in the PROactive Study (PROspective pioglitAzone Clinical Trial In macroVascular Events): a randomised controlled trial. Lancet. 366:1279-1289.
51. Zhang, H., et al. 2005. Collecting duct specific deletion of peroxisome proliferator-activated receptor blocks thiazolidinedione-induced fluid retention. Proc. Natl. Acad. Sci. U. S. A. 102:9406-9411.
52. Guan, Y., et al. 2005. Thiazolidinediones expand body fluid volume through PPARgamma stimulation of ENaC-mediated renal salt absorption. Nat. Med. 11:861-866.
53. Semenkovich, C.F. 2005. TZDs and diabetes: testing the waters. Nat. Med. 11:822-824.
54. Nissen, S.E., Wolski, K., and Topol, E.J. 2005. Effect of muraglitazar on death and major adverse cardiovascular events in patients with type 2 diabetes mellitus. JAMA. 294:2581-2586.
55. UK Prospective Diabetes Study (UKPDS) Group. 1998. Effect of intensive blood-glucose control with metformin on complications in overweight patients with type 2 diabetes (UKPDS 34). Lancet. 352:854-865.
56. Pi-Sunyer, F.X., et al. 2006. Effect of rimonabant, a cannabinoid-1 receptor blocker, on weight and cardiometabolic risk factors in overweight or obese patients. RIO-North America: a randomized controlled trial. JAMA. 295:761-775.
57. MacLennan, S.J., Reynen, P.H., Kwan, J., and Bonhaus, D.W. 1998. Evidence for inverse agonism of SR141716A at human recombinant cannabinoid CB1 and CB2 receptors. Br. J. Pharmacol. 124:619-622.
58. Steffens, S., et al. 2005. Low dose oral cannabinoid therapy reduces progression of atherosclerosis in mice. Nature. 434:782-786.
59. Gosling, J., et al. 1999. MCP-1 deficiency reduces susceptibility to atherosclerosis in mice that overexpress human apolipoprotein B. J. Clin. Invest. 103:773-778.
60. Boring, L., Gosling, J., Cleary, M., and Charo, I.F. 1998. Decreased lesion formation in CCR2-/- mice reveals a role for chemokines in the initiation of atherosclerosis. Nature. 394:894-897.
61. Smith, J.D., et al. 1995. Decreased atherosclerosis in mice deficient in both macrophage colony-stimulating factor (op) and apolipoprotein E. Proc. Natl. Acad. Sci. U. S. A. 92:8264-8268.
62. Haj, F.G., Zabolotny, J.M., Kim, Y.B., Kahn, B.B., and Neel, B.G. 2005. Liver-specific protein-tyrosine phosphatase 1B (PTP1B) re-expression alters glucose homeostasis of PTP1B-/- mice. J. Biol. Chem. 280:15038-15046.
63. Heinonen, K.M., Dube, N., Bourdeau, A., Lapp, W.S., and Tremblay, M.L. 2006. Protein tyrosine phosphatase 1B negatively regulates macrophage development through CSF-1 signaling. Proc. Natl. Acad. Sci. U. S. A. 103:2776-2781.
64. Utiger, R.D. 1995. Altered thyroid function in non-thyroidal illness and surgery. To treat or not to treat? N. Engl. J. Med. 333:1562-1563.
65. Brent, G.A., and Hershman, J.M. 1986. Thyroxine therapy in patients with severe nonthyroidal illnesses and low serum thyroxine concentration. J. Clin. Endocrinol. Metab. 63:1-8.
66. Gardner, D.F., Kaplan, M.M., Stanley, C.A., and Utiger, R.D. 1979. Effect of triiodothyronine replacement on the metabolic and pituitary responses to starvation. N. Engl. J. Med. 300:579-584.
67. Hotamisligil, G.S., and Spiegelman, B.M. 1994. Tumor necrosis factor alpha: a key component of the obesity-diabetes link. Diabetes. 43:1271-1278.
68. Schreyer, S.A., Peschon, J.J., and LeBoeuf, R.C. 1996. Accelerated atherosclerosis in mice lacking tumor necrosis factor receptor p55. J. Biol. Chem. 271:26174-26178.
69. Gerbod-Giannone, M.-C., et al. 2006. TNFalpha induces ABCA1 through NF-kappaB in macrophages and in phagocytes ingesting apoptotic cells. Proc. Natl. Acad. Sci. U. S. A. 103:3112-3117.
70. Kanters, E., et al. 2003. Inhibition of NF-κB activation in macrophages increases atherosclerosis in LDL receptor-deficient mice. J. Clin. Invest. 112:1176-1185. doi:10.1172/JCI200318580.
71. Evans, J.L., Goldfine, I.D., Maddux, B.A., and Grodsky, G.M. 2002. Oxidative stress and stress-activated signaling pathways: a unifying hypothesis of type 2 diabetes. Endocr. Rev. 23:599-622.
72. Ugi, S., Sharma, P.M., Ricketts, W., Imamura, T., and Olefsky, J.M. 2002. Phosphatidylinositol 3-kinase is required for insulin-stimulated tyrosine phosphorylation of Shc in 3T3-L1 adipocytes. J. Biol. Chem. 277:18592-18597.
73. Shi, K., et al. 2004. Protein-tyrosine phosphatase 1B associates with insulin receptor and negatively regulates insulin signaling without receptor internalization. J. Biochem. (Tokyo). 136:89-96.
74. Whiteman, E.L., Chen, J.J., and Birnbaum, M.J. 2003. Platelet-derived growth factor (PDGF) stimulates glucose transport in 3T3-L1 adipocytes overexpressing PDGF receptor by a pathway independent of insulin receptor substrates. Endocrinology. 144:3811-3820.
75. Boucher, P., Gotthardt, M., Li, W.P., Anderson, R.G., and Herz, J. 2003. LRP: role in vascular wall integrity and protection from atherosclerosis. Science. 300:329-332.
76. Baumgartl, J., et al. 2006. Myeloid lineage cell-restricted insulin resistance protects apolipoproteinE-deficient mice against atherosclerosis. Cell Metab. 3:247-256.
77. Han, S., et al. 2006. Macrophage insulin receptor deficiency increases ER stress-induced apoptosis and necrotic core formation in advanced atherosclerotic lesions. Cell Metab. 3:257-266.
78. Camps, M., et al. 2005. Blockade of PI3Kgamma suppresses joint inflammation and damage in mouse models of rheumatoid arthritis. Nat. Med. 11:936-943.
79. Barber, D.F., et al. 2005. PI3Kgamma inhibition blocks glomerulonephritis and extends lifespan in a mouse model of systemic lupus. Nat. Med. 11:933-935.
80. Mason, P.A., Matheson, E.C., Hall, A.G., and Lightowlers, R.N. 2003. Mismatch repair activity in mammalian mitochondria. Nucleic Acids Res. 31:1052-1058.
81. Patti, M.E., et al. 2003. Coordinated reduction of genes of oxidative metabolism in humans with insulin resistance and diabetes: potential role of PGC1 and NRF1. Proc. Natl. Acad. Sci. U. S. A. 100:8466-8471.
82. Petersen, K.F., Dufour, S., Befroy, D., Garcia, R., and Shulman, G.I. 2004. Impaired mitochondrial activity in the insulin-resistant offspring of patients with type 2 diabetes. N. Engl. J. Med. 350:664-671.
83. Du, X., et al. 2006. Insulin resistance reduces arterial prostacyclin synthase and eNOS activities by increasing endothelial fatty acid oxidation. J. Clin. Invest. 116:1071-1080. doi:10.1172/JCI23354.
84. Ballinger, S.W., et al. 2002. Mitochondrial integrity and function in atherogenesis. Circulation. 106:544-549.
85. Levin, M., et al. 2003. Mapping of ATP, glucose, glycogen, and lactate concentrations within the arterial wall. Arterioscler. Thromb. Vasc. Biol. 23:1801-1807.
86. Santerre, R.F., Nicolosi, R.J., and Smith, S.C. 1974. Respiratory control in preatherosclerotic susceptible and resistant pigeon aortas. Exp. Mol. Pathol. 20:397-406.
87. f 0-12 lipoprotein in normal and hypercholesterolaemic serum. Lancet. 2:530-534.
88. Klein, P.D., and Johnson, R.M. 1954. Phosphorus metabolism in unsaturated fatty acid-deficient rats. J. Biol. Chem. 211:103-110.
89. Cornwell, D.G., and Panganamala, R.V. 1981. Atherosclerosis: an intracellular deficiency in essential fatty acids. Prog. Lipid Res. 20:365-376.
90. Bernal-Mizrachi, C., et al. 2005. Vascular respiratory uncoupling increases blood pressure and atherosclerosis. Nature. 435:502-506.
91. Wilson, F.H., et al. 2004. A cluster of metabolic defects caused by mutation in a mitochondrial tRNA. Science. 306:1190-1194.
92. Heaton, J.M. 1972. The distribution of brown adipose tissue in the human. J. Anat. 112:35-39.
93. Tordjman, K., et al. 2001. PPARα deficiency reduces insulin resistance and atherosclerosis in apoE null mice. J. Clin. Invest. 107:1025-1034.
94. Bernal-Mizrachi, C., et al. 2003. Dexamethasone induction of hypertension and diabetes is PPARα-dependent in LDL receptor null mice. Nat. Med. 9:1069-1075.
95. Nisoli, E., et al. 2005. Calorie restriction promotes mitochondrial biogenesis by inducing the expression of eNOS. Science. 310:314-317.
96. Spees, J.L., Olson, S.D., Whitney, M.J., and Prockop, D.J. 2006. Mitochondrial transfer between cells can rescue aerobic respiration. Proc. Natl. Acad. Sci. U. S. A. 103:1283-1288.
97. Lu, T., et al. 2004. Gene regulation and DNA damage in the ageing human brain. Nature. 429:883-891.
98. DeBusk, F.L. 1972. The Hutchinson-Gilford progeria syndrome. Report of 4 cases and review of the literature. J. Pediatr. 80:697-724.
99. Rosenbloom, A.L., et al. 1983. Progeria: insulin resistance and hyperglycemia. J. Pediatr. 102:400-402.
100. Varga, R., et al. 2006. Progressive vascular smooth muscle cell defects in a mouse model of Hutchinson-Gilford progeria syndrome. Proc. Natl. Acad. Sci. U. S. A. 103:3250-3255.
101. Liu, B., et al. 2005. Genomic instability in laminopathy-based premature aging. Nat. Med. 11:780-785.
102. Fong, L.G., et al. 2006. A protein farnesyltransferase inhibitor ameliorates disease in a mouse model of progeria. Science. 311:1621-1623.
103. Gray, M.D., et al. 1997. The Werner syndrome protein is a DNA helicase. Nat. Genet. 17:100-103.
104. Yamada, K., Ikegami, H., Yoneda, H., Miki, T., and Ogihara, T. 1999. All patients with Werner's syndrome are insulin resistant, but only those who also have impaired insulin secretion develop overt diabetes. Diabetes Care. 22:2094-2095.
105. Epstein, C.J., Martin, G.M., Schultz, A.L., and Motulsky, A.G. 1966. Werner's syndrome: a review of its symptomatology, natural history, pathologic features, genetics and relationship to the natural aging process. Medicine (Baltimore). 45:177-221.
106. Bakkenist, C.J., and Kastan, M.B. 2003. DNA damage activates ATM through intermolecular autophosphorylation and dimer dissociation. Nature. 421:499-506.
107. Ihling, C., et al. 1998. Co-expression of p53 and MDM2 in human atherosclerosis: implications for the regulation of cellularity of atherosclerotic lesions. J. Pathol. 185:303-312.
108. Martinet, W., Knaapen, M.W., De Meyer, G.R., Herman, A.G., and Kockx, M.M. 2001. Oxidative DNA damage and repair in experimental atherosclerosis are reversed by dietary lipid lowering. Circ. Res. 88:733-739.
109. Guevara, N.V., Kim, H.S., Antonova, E.I., and Chan, L. 1999. The absence of p53 accelerates atherosclerosis by increasing cell proliferation in vivo. Nat. Med. 5:335-339.
110. Van Vlijmen, B.J., et al. 2001. Macrophage p53 deficiency leads to enhanced atherosclerosis in APOE*3-Leiden transgenic mice. Circ. Res. 88:780-786.
111. Licht, C.L., Stevnsner, T., and Bohr, V.A. 2003. Cockayne syndrome group B cellular and biochemical functions. Am. J. Hum. Genet. 73:1217-1239.
112. Ozcan, U., et al. 2004. Endoplasmic reticulum stress links obesity, insulin action, and type 2 diabetes. Science. 306:457-461.
113. Ricci, R., et al. 2004. Requirement of JNK2 for scavenger receptor A-mediated foam cell formation in atherogenesis. Science. 306:1558-1561.
114. Devries-Seimon, T., et al. 2005. Cholesterol-induced macrophage apoptosis requires ER stress pathways and engagement of the type A scavenger receptor. J. Cell Biol. 171:61-73.
115. Wang, D., Wei, Y., and Pagliassotti, M.J. 2006. Saturated fatty acids promote endoplasmic reticulum stress and liver injury in rats with hepatic steatosis. Endocrinology. 147:943-951.
116. Zhang, K., et al. 2006. Endoplasmic reticulum stress activates cleavage of CREBH to induce a systemic inflammatory response. Cell. 124:587-599.
117. The Diabetes Control and Complications Trial/Epidemiology of Diabetes Interventions and Complications (DCCT/EDIC) Study Research Group. 2005. Intensive diabetes treatment and cardiovascular disease in patients with type 1 diabetes. N. Engl. J. Med. 353:2643-2653.
118. Lalla, E., et al. 2006. Periodontal changes in children and adolescents with diabetes: a case-control study. Diabetes Care. 29:295-299.
119. Beck, J.D., et al. 2001. Relationship of periodontal disease to carotid artery intima-media wall thickness: the Atherosclerosis Risk in Communities (ARIC) study. Arterioscler. Thromb. Vasc. Biol. 21:1816-1822.
120. Gibson, F.C., 3rd, et al. 2004. Innate immune recognition of invasive bacteria accelerates atherosclerosis in apolipoprotein E-deficient mice. Circulation. 109:2801-2806.
121. Backhed, F., et al. 2004. The gut microbiota as an environmental factor that regulates fat storage. Proc. Natl. Acad. Sci. U. S. A. 101:15718-15723.
122. Vikramadithyan, R.K., et al. 2005. Human aldose reductase expression accelerates diabetic atherosclerosis in transgenic mice. J. Clin. Invest. 115:2434-2443. doi:10.1172/JCI24819.
123. Ruef, J., et al. 2000. Involvement of aldose reductase in vascular smooth muscle cell growth and lesion formation after arterial injury. Arterioscler. Thromb. Vasc. Biol. 20:1745-1752.
124. Aprahamian, T., et al. 2004. Impaired clearance of apoptotic cells promotes synergy between atherogenesis and autoimmune disease. J. Exp. Med. 199:1121-1131.
125. van den Elzen, P., et al. 2005. Apolipoprotein-mediated pathways of lipid antigen presentation. Nature. 437:906-910.